| Autor: |
Ken-Opurum J; Axtria Inc., Decision Science, Health Economics and Outcomes Research / Real-World Evidence, Berkley Heights, NJ 07922, USA., Srinivas SS; Axtria Inc., Decision Science, Health Economics and Outcomes Research / Real-World Evidence, Berkley Heights, NJ 07922, USA., Vadagam P; Axtria Inc., Decision Science, Health Economics and Outcomes Research / Real-World Evidence, Berkley Heights, NJ 07922, USA., Faith L; Axtria Inc., Decision Science, Health Economics and Outcomes Research / Real-World Evidence, Berkley Heights, NJ 07922, USA., Park S; Sanofi US, US General Medicines, Bridgewater, NJ 08807, USA., Charland S; Sanofi US, US General Medicines, Bridgewater, NJ 08807, USA., Revel A; Sanofi US, US General Medicines, Bridgewater, NJ 08807, USA., Preblick R; Sanofi US, US General Medicines, Bridgewater, NJ 08807, USA. |
| Abstrakt: |
Aim: The budgetary consequences of increasing dronedarone utilization for treatment of atrial fibrillation were evaluated from a US payer perspective. Materials & methods: A budget impact model over a 5-year time horizon was developed, including drug-related costs and risks for long-term clinical outcomes (LTCOs). Treatments included antiarrhythmic drugs (AADs; dronedarone, amiodarone, sotalol, propafenone, dofetilide, flecainide), rate control medications, and ablation. Direct comparisons and temporal and non-temporal combination scenarios investigating treatment order were analyzed as costs per patient per month (PPPM). Results: By projected year 5, costs PPPM for dronedarone versus other AADs decreased by $37.69 due to fewer LTCOs, treatment with dronedarone versus ablation or rate control medications + ablation resulted in cost savings ($359.94 and $370.54, respectively), and AADs placed before ablation decreased PPPM costs by $242 compared with ablation before AADs. Conclusion Increased dronedarone utilization demonstrated incremental cost reductions over time. |
